Abstract: The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems.

Abstract: The invention relates to novel solid forms of fluoroquinolones, in particular to complex co-crystals and to solvates, hydrates and polymorphs thereof. These substances can be used to prepare a pharmaceutical composition containing same as an active ingredient, which can be used as an antibiotic. The compounds have a storage stability that is constant and above that of the salts or hydrates thereof.

Abstract: The present invention relates to co-crystals of tadalafil with hydroxyl-substituted benzoic acid coformers having the following structure. Said co-crystals can be used to produce a pharmaceutical composition containing the same as the useful active ingredient. Said co-crystals can exhibit a constant storage stability.

Abstract: The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.

Abstract: The present invention refers to pharmaceutical combinations of two antiepileptic substances and also to combinations of an antiepileptic and B-complex vitamins, in which the antiepileptic substances are selected from pregabalin and oxcarbazepine, and the vitamins are selected from vitamin B1 and vitamin B12. The invention also relates to pharmaceutical compositions containing said combinations and to the use of said compositions for treating neuropathic pain (NP).

Abstract: The present invention relates to a salt of a pyrimidin derivative of the acid (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic, to a method for preparing same and to the use thereof in formulating pharmaceutical formulations.

Abstract: The invention relates to novel solid forms of fluoroquinolones, in particular to complex co-crystals and to solvates, hydrates and polymorphs thereof. These substances can be used to prepare a pharmaceutical composition containing same as an active ingredient, which can be used as an antibiotic. The compounds have a storage stability that is constant and above that of the salts or hydrates thereof.

Abstract: The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems.

Abstract: The present invention relates to a salt of a pyrimidin derivative of the acid (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic, to a method for preparing same and to the use thereof in formulating pharmaceutical formulations.

Abstract: The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.

Abstract: A modified-release oral pharmaceutical composition in capsules with microspheres contains loratadine, phenylephrine and pharmaceutically acceptable excipients. The composition has immediate bioavailability, with plasmatic concentration values within the therapeutic window with a uniform, continuous release. A method for the production of the composition and a method for treatment as a nasal decongestant and an antihistamine are included.

Abstract: The invention relates to a solid oral pharmaceutical composition combining ketorolac and B-complex consisting of inter alia thiamin, pyridoxine and cyanocobalamin (vitamins B1, B6 and B12 respectively) and/or the pharmaceutically acceptable salts thereof, as well as pharmaceutically acceptable excipients and/or vehicles. The invention also relates to the method for producing the composition and to the use of said composition having a synergistic therapeutic activity, indicated for the treatment of moderate to severe pain or neuralgias in different locations.

Abstract: The invention relates to a modified release pharmaceutical composition in capsules with coated microspheres, combining two active ingredients with radically different plasma concentration times, namely a muscle relaxant (tizanidine) and a non-steroidal anti-inflammatory drug (meloxicam), and pharmaceutically acceptable excipients or vehicles; as well as a method for producing the composition and the use of said combination for the preparation of a drug having synergic therapeutic effect in the treatment of spasticity, disorders related to the skeletal muscle and/or muscular ailments, and moderate to severe pain in general.